(PA-180) Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next-Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis
Location: Room 714A
Abstract Presenter: Yuntong Liu, liuyuntong@ihcam.ac.cn – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
MRD and Biomarkers
Thursday, Sep 18th
15:08 - 15:16 East Coast USA Time
(OA-62) Dynamic Prediction of Progression Based on Minimal Residual Disease (MRD) in Patients with Newly Diagnosed Transplant Eligible Multiple Myeloma
Location: Hall FG
Abstract Presenter: Anna Smit, MSc – Department of Hematology, Erasmus University Medical Center Cancer Institute
MRD and Biomarkers
Friday, Sep 19th
12:35 - 12:41 East Coast USA Time
(PA-199) Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma
(OA-23) Circulating Tumor Cells for the Staging of Multiple Myeloma: First Results of a European Pooled Analysis of 2432 Patients with Newly Diagnosed Multiple Myeloma and Plasma Cell Leukemia
Location: Room 718
Abstract Presenter: Luca Bertamini, MD (he/him/his) – Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
MRD and Biomarkers
Saturday, Sep 20th
08:20 - 08:30 East Coast USA Time
(OA-25) High Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial
Location: Room 718
Abstract Presenter: Mattia D'Agostino, MD – Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
MRD and Biomarkers
Saturday, Sep 20th
08:30 - 08:40 East Coast USA Time
(OA-22) Comparative Analysis of Four NGS Protocols for Measurable Residual Disease Assessment Testing ctDNA and Bone Marrow Samples in Multiple Myeloma
Location: Room 718
Abstract Presenter: Silvia Armuzzi, MS (she/her/hers) – Department of Medical and Surgical Sciences - University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna
MRD and Biomarkers
Saturday, Sep 20th
08:40 - 08:50 East Coast USA Time
(OA-24) Assessment For Circulating Plasma Cell Enhances R2-ISS in Newly Diagnosed Multiple Myeloma
